- Metered Dose Inhaler
- Dry Powder Inhaler
The respiratory inhaler devices market is expected to reach USD 41098 million by 2028 and will grow at a CAGR of 5.84% during the forecast period 2022 to 2028. Respiratory Inhaler Devices are the medical devices that deliver the medication to prevent or control the chronic obstructive pulmonary disease (COPD), asthma, and other respiratory disorders. Various types of respiratory inhaler devices are available in the market such as metered dose inhaler, dry powder inhaler, and nebulizer. Escalation in the number of industries led to an abnormal increase in environmental pollution that causes respiratory diseases such as COPD and asthma might propel the market. According to World Health Organization approximately 3 Mn deaths were observed in 2015 around the globe. Increase in the tobacco consumption majorly in middle and low income countries may causes respiratory disorders and which in turn drive the market. Moreover, most of the market players are focusing on the development of newer respiratory inhaler devices which are more convenient for drug administration.Â Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies followed by market players for garnering larger revenue share in market. For instance, in April 2016, AstraZeneca received FDA approval for Bevepsi Aeresphere (glycopyrrolate and formoterol fumarate) inhalation aerosol used in chronic obstructive pulmonary disease (COPD). In addition, in January 2016, Novartis AG collaborated with Qualcomm, Inc. for the innovation of digital technology for Breezhaler inhaler used in the treatment of COPD. For instance, in August 2014, Sandoz received Mexicoâ€™s Health Authority (COFEPRIS) approval for the marketing of Airflusal Forspiro used in COPD. Middle East and Africa market driven by product launchings by the market players in Africa region. For instance, in January 2017, Cipla launched respiratory inhaler Synchrobreathe in South Africa. Moreover, increase in tobacco consumption and increase in pollution due to increasing the number of industries are anticipated to boost the market in the region.
Fastest Growing Market
Increase in the prevalence of COPD, asthma, and other respiratory disorder, technological advancements in respiratory inhaler devices, rapid industrialization and rise in smoking population are anticipated to fuel the market. Moreover, ease of administration of drug with respiratory inhaler devices, cost-effective of the products, and growing newborn babies and geriatric population who often exposed to one or the other respiratory disorders are anticipated to boost the respiratory inhaler devices market over the forecast period. However, adverse effects associated with drug inhalation, product recalls, lack of single effective inhalers for all types of disease, and lack of awareness about respiratory inhalers in underdeveloped countries expected to hamper the growth of the market over the forecast timeframe.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.